Crown Bioscience’s New Model Development Center in Kannapolis, North Carolina

Image Credits: Via Ritzau

Announcement

The Crown Bioscience, a leading contract research organization (CRO) headquartered in the United States and a significant part of JSR Life Sciences and Japan-built JSR corporation, inaugurated the state-of-the-art model development center in Kannapolis, North Carolina. This brilliant investment will extend the company’s operation and improve the potency to enable advanced preclinical oncology models, consisting of patient-oriented PDX warm models, PDX-based organoids (PDXO), patient-derived organoids (PDO), and xenografts (PDX) to meet the emerging needs of the biotechnology and pharmaceutical industries.

Excellent Facilities at the New Center

The new facility will power up Crown Bioscience’s US-related potential and is linked with its expansion strategy to enable access to the localized and scientific expertise and the quality preclinical services. With the movement in regulatory frameworks and precision medicine, the revolutionization has peaked due to the rising demand for scalable, translatable, properly aligned, and innovative models contributing to the recent drug development within the market spectrum is emerging mainly in the space where Crown Bioscience is known and encouraged to play a lead role.

By targeting advancement on the clinically relevant oncology models, the new center will contribute largely to Crown Bioscience’s model platform portfolio via partnership with the different facilities. It will also leverage the value of organoid and 3D cell culture, following the major industry developments. The development includes a peaked market demand for PDX and organoid models in the oncology drug development and advancements in the organoid systems, bioprinting technologies, and 3D cell culture. The FDA Modernization Act 2.0, authorized on 9th April 2025, highlighted the options to animal testing. Also, the increasing guidance from the Human Genetic Resources Administration of China (HGRAC) on the export of Chinese-based PDX samples counts as one of the effective developments.

Current Status of the New Center

In October will complete its operative procedure. The Kannapolis site is forecasting the expansion of its service capabilities, best suited to the business needs. The roles will characterize the study management, laboratory operations, and oncology research, alongside unlocking opportunities for local talent and impressing scientific expertise on the region. Apart from boosting the company’s US footprint, the facility will support the local economy via training, long-term community investment, and job creation.

CEO of Crown Bioscience, John Gu, said, “Kannapolis is beyond the additional facility; it’s like a catalyst for what else we have to offer to the next generation of oncology research.”